ストックスクリーナーアプリを入手
154.36
1.81%
-2.85
アフターアワーズ：
154.58
0.22
+0.14%
Neurocrine Biosciences Inc (NBIX) 最新ニュース
New CRENESSITY Dosing Algorithms And INGREZZA Data Might Change The Case For Investing In Neurocrine Biosciences (NBIX) - simplywall.st
Morgan Stanley lists Rule 144 sale of NBIX-linked shares | NBIX SEC FilingForm 144 - Stock Titan
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Value Gem With Solid Fundamentals - ChartMill
New data support early use of Ingrezza in mild tardive dyskinesia - The Pharma Letter
Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal - RTTNews
Neurocrine Biosciences Says Data Show Functional Improvement in Tardive Dyskinesia With Ingrezza Capsules - Moomoo
Richard F. Pops, Neurocrine Biosciences director, sells $2.36m in stock By Investing.com - Investing.com Australia
Neurocrine presents real-world data on tardive dyskinesia drug - Investing.com UK
Richard F. Pops, Neurocrine Biosciences director, sells $2.36m in stock - Investing.com
Neurocrine (NBIX) director sells 15,000 shares under 10b5-1 plan - Stock Titan
Neurocrine Biosciences Finalizes $2.9 Billion Acquisition of Soleno Therapeutics - Moomoo
Neurocrine presents real-world data on tardive dyskinesia drug By Investing.com - Investing.com Australia
Neurocrine presents data on INGREZZA treatment for mild tardive dyskinesia - StreetInsider
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules - PR Newswire
Neurocrine Biosciences completes $2.9 billion Soleno acquisition - Investing.com UK
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B - Contract Pharma
Neurocrine Biosciences, Inc. completed the acquisition of Soleno Therapeutics, Inc. from Anish Bhatnagar, James Mackaness, and others. - marketscreener.com
Neurocrine Biosciences Acquires Soleno Therapeutics, Adds VYKAT XR for Prader-Willi Syndrome to Rare Disease Portfolio - Minichart
Soleno Therapeutics Announces Acquisition by Neurocrine Biosciences and Corporate Changes – SEC Form 8-K Filing - Minichart
Neurocrine Closes $2.9 Billion Soleno Acquisition to Expand Rare Disease Portfolio - citybiz
Neurocrine Biosciences completes $2.9 billion Soleno acquisition By Investing.com - Investing.com Australia
Neurocrine Biosciences completes acquisition of Soleno Therapeutics - marketscreener.com
Soleno Therapeutics completes merger with Neurocrine Biosciences, delists from Nasdaq - Investing.com
Neurocrine Biosciences Completes Acquisition Of Soleno Therapeutics - TradingView
Soleno Therapeutics (NASDAQ: SLNO) taken private at $53 per share in cash deal - Stock Titan
Soleno Therapeutics (NASDAQ: SLNO) deregisters S-3 after Neurocrine merger - Stock Titan
Neurocrine Biosciences (NASDAQ: NBIX) completes $2.9B Soleno acquisition - Stock Titan
Neurocrine completes Soleno buyout (NASDAQ: SLNO) at $53.00 per share - Stock Titan
Neurocrine (SLNO) completes tender offer; ~46.36M Soleno shares tendered - Stock Titan
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics - ChartMill
Ionis Pharmaceuticals Touts $3B TRYNGOLZA Opportunity, Pipeline Readouts at Conference - Yahoo Finance
Neurocrine Biosciences (NBIX) Stock Analysis: Strong Buy Ratings and 20% Upside Potential - DirectorsTalk Interviews
Neurocrine to buy Soleno Therapeutics for $2.9 billion - MSN
Neurocrine Biosciences stock (US64125C1099): momentum after strong run in May and growing neuroscien - AD HOC NEWS
[144] NEUROCRINE BIOSCIENCES INC SEC Filing - Stock Titan
NBIX Stock Price, Quote & Chart | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill
Neurocrine Biosciences director Norwalk sells $590,601 in stock By Investing.com - Investing.com Canada
Neurocrine Biosciences director Norwalk sells $590,601 in stock - Investing.com
Neurocrine (NBIX) director pre-plans sale of 3,810 shares via 10b5-1 plan - Stock Titan
Neurocrine Biosciences stock (US64125C1099): Recent clinical trial advancements and market position - AD HOC NEWS
Neurocrine reaffirms $2.7B-$2.8B INGREZZA outlook while acquisition of Soleno remains on track for Q2 close - MSN
Neurocrine Biosciences stock hits all-time high at 160.31 USD By Investing.com - Investing.com Nigeria
A Look at Neurocrine Biosciences Inc (NBIX) After 3.5% Gain -- G - GuruFocus
Neurocrine Biosciences stock hits all-time high at 160.31 USD - Investing.com
Neurocrine Biosciences (NBIX) Valuation After Strong Q1 2026 Results And New CRENESSITY And Obesity Pipeline Updates - simplywall.st
Number of shareholders of Neurocrine Biosciences, Inc. – MIL:1NBIX - TradingView
Neurocrine Biosciences stock (US64125C1099): Q1 2026 earnings beat with $815M revenue - AD HOC NEWS
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a Peter Lynch-Style GARP Opportunity - ChartMill
Neurocrine stock soars 61% after InvestingPro Fair Value signal By Investing.com - Investing.com Canada
Neurocrine Biosciences (NBIX) Is Up 13.6% After Q1 Beat And New CRENESSITY Data ReleaseHas The Bull Case Changed? - simplywall.st
Earnings call transcript: Neurocrine Biosciences Q1 2026 earnings beat expectations By Investing.com - Investing.com South Africa
Earnings call transcript: Neurocrine Biosciences Q1 2026 earnings beat expectations - Investing.com
2.84%
大文字化:
|
ボリューム (24 時間):